Welcome to our dedicated page for Madrigal Pharmaceuticals news (Ticker: $MDGL), a resource for investors and traders seeking the latest updates and insights on Madrigal Pharmaceuticals stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Madrigal Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Madrigal Pharmaceuticals's position in the market.
Rhea-AI Summary
Madrigal Pharmaceuticals announces the submission of Marketing Authorization Application for resmetirom for NASH treatment, supported by positive Phase 3 trial results. Resmetirom aims to target key causes of NASH and has shown efficacy in reducing fibrosis and resolving NASH. The drug is under review with the FDA and EMA, with potential approval in Europe and the US.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.78%
Tags
-
Rhea-AI Summary
Madrigal Pharmaceuticals, Inc. appoints Mardi C. Dier as Chief Financial Officer, bringing over 20 years of biopharmaceutical financial leadership experience. Ms. Dier's background includes roles at Portola Pharmaceuticals, Ultragenyx Pharmaceutical, Inc., and Acelyrin, Inc. She joins Madrigal to support the launch of resmetirom and lead the company's growth in the NASH sector.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.02%
Tags
-
Rhea-AI Summary
Madrigal Pharmaceuticals, Inc. appoints Mardi C. Dier as Chief Financial Officer and anticipates resmetirom to be the first medicine approved for NASH with a PDUFA date of March 14, 2024. The company reports year-end 2023 cash, cash equivalents, and marketable securities of $634 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.02%
Tags
Rhea-AI Summary
Madrigal Pharmaceuticals, Inc. (MDGL) granted equity awards to 46 new employees under the 2023 Inducement Plan. The awards include options to purchase 1,091 shares and 11,712 time-based restricted stock units. The options have an exercise price of $222.22 per share and vest over time, while the restricted stock units vest in increments over four years.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.64%
Tags
-
Rhea-AI Summary
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) announced the publication of the pivotal Phase 3 MAESTRO-NASH trial of resmetirom in the New England Journal of Medicine. Resmetirom is the first investigational medicine for NASH to achieve fibrosis improvement and NASH resolution primary endpoints in a Phase 3 trial. It has the potential to become the first and only medicine approved for NASH, with a PDUFA date of March 14, 2024. The FDA granted resmetirom Priority Review and Breakthrough Therapy designation. The safety profile of resmetirom has been reinforced, and it is under review to become the first medicine approved to treat patients with NASH with liver fibrosis. The publication will provide clinicians with valuable information in treating NASH, a leading cause of liver-related mortality globally.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.11%
Tags
-
Rhea-AI Summary
Madrigal Pharmaceuticals, Inc. announced the granting of equity awards to seven new employees under the 2023 Inducement Plan. The awards include options to purchase 24,538 shares of common stock, time-based restricted stock units, and market-based performance stock units. The options have an exercise price of $222.23 per share and vest over time, while the restricted stock units vest in increments over four years. The MSUs vest upon certification of stock price performance until December 31, 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.4%
Tags
Rhea-AI Summary
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) announces the addition of three new leaders to its team: Mark Barrett as Chief Business Officer, Clint Wallace as Chief Human Resources Officer, and Tina Ventura as Chief Investor Relations Officer. These leaders bring extensive experience in biopharmaceuticals, human resources, and investor relations. The company is preparing for a first-to-market launch of resmetirom in NASH with significant fibrosis, focusing on enduring leadership and growth.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.45%
Tags
-
Rhea-AI Summary
Madrigal Pharmaceuticals, Inc. announced the granting of equity awards to 109 new employees under the company's 2023 Inducement Plan. The employees received options to purchase 14,206 shares of Madrigal’s common stock and 32,788 time-based restricted stock units. The options have an exercise price of $243.92 per share and vest over time, while the restricted stock units vest in increments over four years.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.96%
Tags
-
Rhea-AI Summary
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) presented five health economics abstracts at the NASH-TAG Conference, highlighting the serious clinical burden of uncontrolled NASH and identifying opportunities to improve patient care. An analysis of patient records from a large claims database revealed that the risk of progressing to cirrhosis, decompensated cirrhosis, liver transplant, or all-cause death increased from 10.5% after one year to 31.4% after 5 years in patients with noncirrhotic NASH.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.96%
Tags
Rhea-AI Summary
Madrigal Pharmaceuticals, Inc. (MDGL) to present at 42nd Annual J.P. Morgan Healthcare Conference on January 10, 2024
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.96%
Tags
Madrigal Pharmaceuticals, Inc.
Nasdaq:MDGL
MDGL Rankings
MDGL Stock Data
4.51B
12.78M
9.24%
94.65%
16.3%
Pharmaceutical Preparation Manufacturing
Manufacturing
United States of America
WEST CONSHOHOCKEN
About MDGL
madrigal pharmaceuticals inc. is a biotechnology company based out of calle laguna del marquesado nª 19, nave 16 edificio adriana 1ª planta, polígono industrial la resina (villaverde), madrid, community of madrid, spain.